Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen
JavaScript is disabled for your browser. Some features of this site may not work without it.
| dc.contributor.author | Singh, Sanjay
|
|
| dc.contributor.author | Gumbo, Tawanda
|
|
| dc.contributor.author | Alffenaar, Jan-Willem
|
|
| dc.contributor.author | Boorgula, Gunavanthi D.
|
|
| dc.contributor.author | Shankar, Prem
|
|
| dc.contributor.author | Thomas, Tania A.
|
|
| dc.contributor.author | Dheda, Keertan
|
|
| dc.contributor.author | Malinga, Lesibana Anthony
|
|
| dc.contributor.author | Raj, Prithvi
|
|
| dc.contributor.author | Aryal, Santosh
|
|
| dc.contributor.author | Srivastava, Shashikant
|
|
| dc.date.accessioned | 2024-05-27T08:41:58Z | |
| dc.date.issued | 2023-12 | |
| dc.description | DATA AVAILABILITY STATEMENT : Upon a reasonable request, the raw data for the results presented in the manuscript are available from the corresponding author. | en_US |
| dc.description.abstract | Please read abstract in the article. | en_US |
| dc.description.department | Medical Microbiology | en_US |
| dc.description.embargo | 2024-10-23 | |
| dc.description.librarian | hj2024 | en_US |
| dc.description.sdg | SDG-03:Good heatlh and well-being | en_US |
| dc.description.sponsorship | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the University of Texas System STARS award, the Department of Pulmonary Immunology, UT Health Science Center at Tyler, Texas, USA. | en_US |
| dc.description.uri | http://www.elsevier.com/locate/ijantimicag | en_US |
| dc.identifier.citation | Singh, S., Gumbo, T., Alffenaar, J.-W. et al. 2023, 'Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen', International Journal of Antimicrobial Agents, vol. 62, no. 6, art. 106968, pp. 1-8, doi : 10.1016/j.ijantimicag.2023.106968. | en_US |
| dc.identifier.issn | 0924-8579 (print) | |
| dc.identifier.issn | 1872-7913 (online) | |
| dc.identifier.other | 10.1016/j.ijantimicag.2023.106968 | |
| dc.identifier.uri | http://hdl.handle.net/2263/96243 | |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier | en_US |
| dc.rights | © 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved. Notice : this is the author’s version of a work that was accepted for publication in International Journal of Antimicrobial Agents. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. A definitive version was subsequently published in International Journal of Antimicrobial Agents, vol. 62, no. 6, art. 106968, pp. 1-8, doi : 10.1016/j.ijantimicag.2023.106968. | en_US |
| dc.subject | Beta-lactams | en_US |
| dc.subject | Pharmacokinetics | en_US |
| dc.subject | Pharmacodynamics | en_US |
| dc.subject | Tuberculosis (TB) | en_US |
| dc.subject | β-lactamase inhibitors (BLIs) | en_US |
| dc.subject | Bedaquiline-pretonamid-linezolid (BPaL) | en_US |
| dc.subject | Hollow fiber model system | en_US |
| dc.subject | Multidrug-resistant tuberculosis (MDR-TB) | en_US |
| dc.subject | Mycobacterium tuberculosis (MTB) | en_US |
| dc.subject | SDG-03: Good health and well-being | en_US |
| dc.title | Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen | en_US |
| dc.type | Postprint Article | en_US |
